Skip to main content
Premium Trial:

Request an Annual Quote

Talking Cuts

Johnson and Johnson executives discussed the company's plan to cut 6 to 7 percent of its workforce and Jacob Goldstein at the Wall Street Journal's Health Blog blogged it live. The cuts, once all in place, are estimated to save the company $1.4 to $1.7 billion a year. Dominic Caruso, the J&J CFO, says that the "position eliminations" will be across all business and later adds that "the large majority of the [projected] savings are due to the workforce reductions." He also says that Johnson and Johnson will continue to cut "the overall level of R&D expense, particularly in the pharma business."

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.